# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K233932   
B Applicant Abbott Laboratories   
C Proprietary and Established Names Alinity i Toxo IgM   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LGD</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.3780 -Toxoplasma GondiiSerological Reagents</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: Clearance of a new device   
B Measurand: IgM antibody to Toxoplasma gondii   
C Type of Test: Chemiluminescent Microparticle Immunoassay (CMIA)

# III Intended Use/Indications for Use:

# A Intended Use(s):

The Alinity i Toxo IgM assay is a chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of $\mathrm { I g M }$ antibodies to Toxoplasma gondii in human serum, serum separator, and plasma tubes (lithium heparin, lithium heparin separator, and tripotassium EDTA) on the Alinity i system.

The Alinity i Toxo IgM assay is to be used as an aid in the diagnosis of acute or recent Toxoplasma gondii infection in suspected individuals including women of child-bearing age. It is recommended that the assay be performed in conjunction with a Toxoplasma gondii IgG assay.

The Alinity i Toxo IgM assay has not been cleared for use in screening blood, plasma, or tissue donors.

B Indication(s) for Use: NA

# C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

Performance has not been established for the use of bodily fluids other than human serum or plasma.

D Special Instrument Requirements:

Alinity i system

# IV Device/System Characteristics:

# A Device Description:

The Alinity i system is a fully automated immunoassay analyzer using chemiluminescent microparticle immunoassay (CMIA) technology. The Alinity i Toxo IgM immunoassay requires the use of Alinity i Toxo IgM Reagent Kit (cartridges, microparticles, and conjugate), Alinity i Toxo IgM Calibrator, and the Alinity i Toxo IgM Controls (positive and negative). The Alinity i Toxo IgM immunoassay components, reagent kit, calibrator and controls are packaged separately and designed to be used on the Alinity i system.

# B Principle of Operation:

The Alinity i Toxo IgM assay is an automated, two-step immunoassay for the qualitative detection of IgM antibodies to Toxoplasma gondii in human serum and plasma using chemiluminescent microparticle immunoassay (CMIA) technology.

Pre-diluted sample and anti-human IgM murine monoclonal antibody coated paramagnetic microparticles are combined and incubated. Together with IgM antibodies of other specificities, anti-Toxo specific IgM present in the sample binds to the anti-human IgM murine monoclonal antibody coated microparticles, forming an antibody-antibody complex. The mixture is washed. A conjugate complex consisting of an acridinium-labeled anti-Toxo $\mathsf { p } 3 0$ antigen murine monoclonal F(ab')2 fragment and native Toxoplasma gondii lysate, containing the $\mathsf { p } 3 0$ antigen, is added to create a reaction mixture and incubated. This conjugate complex is bound by anti-Toxo specific $\mathrm { I g M }$ that has been captured by the anti-human IgM murine monoclonal antibody coated microparticles, forming an antibody-antibody-conjugate complex. Following a wash cycle, PreTrigger and Trigger Solutions are added.

The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the amount of anti-Toxo IgM in the sample and the RLU detected by the system optics. The presence or absence of anti-Toxo IgM in the sample is determined by comparing the chemiluminescent RLU in the reaction to the cutoff RLU determined from an active calibration.

The cutoff is $1 . 0 0 \mathrm { S } / \mathrm { C O }$ . The Alinity i system automatically calculates the signal-to-cutoff (S/CO) ratios, and interprets the results as presented in Table 1.

Table 1: Alinity i Toxo IgM Results Interpretation   

<table><tr><td>S/CO</td><td>Instrument Interpretation</td><td>Retest Procedure</td></tr><tr><td>&lt; 0.83 S/CO</td><td>Nonreactive for IgM antibodies to Toxoplasma gondii</td><td>Individuals with such results are presumed not to be recently infected with Toxoplasma gondii and susceptible to acute</td></tr><tr><td>0.83 to &lt; 1.00 S/CO</td><td>Grayzone/Equivocal</td><td>infection. No retest is required. Specimens that are considered grayzone/equivocal may contain low levels of anti-Toxo IgM. It is recommended to take a second sample within a reasonable period of time (e.g. 2 weeks) and to repeat Alinity i</td></tr><tr><td>≥ 1.00 S/CO</td><td>Reactive for IgM antibodies to Toxoplasma gondii</td><td>Toxo IgM testing. Individuals that are considered reactive for anti-Toxo IgM are presumed to have an acute or recent infection with Toxoplasma gondii. No retest is required.</td></tr></table>

# V Substantial Equivalence Information:

A Predicate Device Name(s): Vidas Toxoplasma gondii IgM Asssay

# C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">PredicateK923166</td><td colspan="1" rowspan="1">Candidate TestK233932</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">VIDAS TOXO IgM Assay</td><td colspan="1" rowspan="1">Alinity i Toxo IgM</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor Use</td><td colspan="1" rowspan="1">The VIDAS TOXO IgM(TXM) assay is intended foruse on the instruments ofthe VIDAS family (VITEKImmunoDiagnostic AssaySystem) as an automatedenzyme-linked fluorescentimmunoassay (ELFA) forthe presumptive qualitativedetection of anti-Toxoplasma gondii IgMantibodies in human serum,as an aid in the diagnosis ofacute, recent, or reactivatedToxoplasma gondiiinfection. This assay mustbe performed in conjunctionwith an anti-Toxoplasmagondii lgG antibody assay.VIDAS TOXO IgM (TXM)assay performance has notbeen established for prenatalscreening or newborntesting. This assay has notbeen cleared by the FDA forblood/plasma donorscreening.</td><td colspan="1" rowspan="1">The Alinity i Toxo IgMassay is achemiluminescentmicroparticleimmunoassay (CMIA)used for the qualitativedetection of IgMantibodies to Toxoplasmagondii in human serum,serum separator, andplasma tubes (lithiumheparin, lithium heparinseparator, andtripotassium EDTA) onthe Alinity i system.The Alinity i Toxo IgMassay is to be used as anaid in the diagnosis ofacute or recentToxoplasma gondiiinfection in suspectedindividuals includingwomen of child-bearingage. It is recommendedthat the assay beperformed in conjunctionwith a Toxoplasma gondiiIgG assay.The Alinity i Toxo IgMassay has not been clearedfor use in screeningblood, plasma, or tissuedonors.</td></tr><tr><td colspan="1" rowspan="1">Calibrator(s)</td><td colspan="1" rowspan="1">1 Calibrator</td><td colspan="1" rowspan="1">1 Calibrator</td></tr><tr><td colspan="1" rowspan="1">Control(s)</td><td colspan="1" rowspan="1">2 (Negative and Positive)</td><td colspan="1" rowspan="1">2 (Negative and Positive)</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Differences</td></tr><tr><td colspan="1" rowspan="1">Antigen and Antibody Used</td><td colspan="1" rowspan="1">Anti-Toxoplasma p30antigen antibody (murine,monoclonal) and nativeToxoplasma gondii lysateAnti-human IgM murinemonoclonal antibody</td><td colspan="1" rowspan="1">Immunocomplex of T.gondii antigen (RHSabin strain)Mouse monoclonalanti-P30 antibodies</td></tr><tr><td colspan="1" rowspan="1">Type of Specimen</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Serum and Plasma</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Enzyme-linked fluorescentimmunoassay</td><td colspan="1" rowspan="1">Chemiluminescentmicroparticleimmunoassay</td></tr><tr><td colspan="1" rowspan="1">Interpretation of Results</td><td colspan="1" rowspan="1">Negative: &lt; 0.55 Test ValueEquivocal: ≥ 0.55 to &lt; 0.65Test ValuePositive: ≥ 0.65 Test Value</td><td colspan="1" rowspan="1">Nonreactive: &lt; 0.83 S/COGrayzone/Equivocal: 0.83to &lt; 1.00 S/COReactive: ≥ 1.00 S/CO</td></tr><tr><td colspan="1" rowspan="1">Components</td><td colspan="1" rowspan="1">Solid Phase Receptacle(SPR) - SPR coated goatanti-µ chain antibodiesReagent Strip - Stripconsists of 10 wells coveredwith labeled, foil seal. Thewells contain the variousreagents required for theassay including:Sample diluent: 300 μLof TRIS buffered saline(0.05 mol/L, pH 7.4) withprotein and chemicalstabilizers and 1 g/Lsodium azide.Pre-wash: 600 μL ofTRIS buffered saline(0.05 mol/L, pH 7.4) withprotein and chemicalstabilizers and 1 g/Lsodium azide.Wash buffer: 600 µL ofTRIS buffered saline(0.05 mol/L, pH 7.4) withprotein and chemicalstabilizers and 1 g/Lsodium azide.Conjugate: 400 μL ofimmunocomplex ofT. gondii antigen (RHSabin strain) grown inmice (9) and mouse</td><td colspan="1" rowspan="1">Microparticles  Anti-human IgM (murine,monoclonal) antibodycoated microparticles inTRIS buffer with protein(bovine and goat)stabilizers, and detergent.Minimum concentration:0.08 % solids.Preservatives:antimicrobial agents.Conjugate - Conjugatecomplex consisting ofacridinium-labeled anti-Toxoplasma p30 antigenantibody (murine,monoclonal) and nativeToxoplasma gondii lysatein phosphate buffer withprotein (bovine)stabilizer, and detergent.Minimum concentration:25 μg/mL. Preservative:sodium azide.</td></tr><tr><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">monoclonal anti-P30antibodies conjugated toalkaline phosphatase withgentamycin 0.02% and0.9 g/L sodium azide.Reading cuvette withsubstrate: 4-Methyl-umbelliferyl phosphate(0.6 mmol/L) +diethanolamine (DEA)(0.62 mol/L or 6.6%,pH 9.2) + 1 g/L sodiumazide (300 μL).</td><td colspan="1" rowspan="1">−</td></tr><tr><td colspan="1" rowspan="1">Calibration Storage</td><td colspan="1" rowspan="1">14 days</td><td colspan="1" rowspan="1">Maximum of 30 days</td></tr></table>

# VI Standards/Guidance Documents Referenced:

# Standards

• CLSI EP05-A3, Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline–Third Edition CLSI EP07 3rd ed., Interference Testing in Clinical Chemistry CLSI EP37 1st ed., Supplemental Tables for Interference Testing in Clinical Chemistry CLSI EP12-A2, User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline— Second Edition

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

# 1. Precision/Reproducibility:

Within-Laboratory Precision: A 20-day within-laboratory precision study was conducted using 3 lots of the Alinity i Toxo IgM reagents, 3 lots of the Alinity i Toxo IgM Calibrator, 3 lots of the Alinity i Toxo IgM Controls, and 1 Alinity i system. Two controls and 4 recalcified human plasma samples (representing serum matrix) were tested in 3 replicates at 2 separate times per day over 20 days using 3 reagent lot/calibrator lot combinations, where a unique reagent lot and a unique calibrator lot are paired. The within laboratory precision data summary is shown in Table 2.

Table 2: Alinity i Toxo IgM Assay Within-Laboratory Precision   

<table><tr><td rowspan=2 colspan=1>SampleID</td><td rowspan=2 colspan=1>n</td><td rowspan=2 colspan=1>Mean(S/CO)</td><td rowspan=1 colspan=2>Repeatability(Within-Run)</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot a</td><td rowspan=1 colspan=2>Overall WithinLaboratory b</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Negative Control</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>NAc</td></tr><tr><td rowspan=1 colspan=1>PositiveControl</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>2.72</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.104</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>358d</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.015</td><td rowspan=1 colspan=1>NAc</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>0.028</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.027</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>NAc</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>359d</td><td rowspan=1 colspan=1>1.34</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>359d</td><td rowspan=1 colspan=1>2.54</td><td rowspan=1 colspan=1>0.078</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.073</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.109</td><td rowspan=1 colspan=1>4.3</td></tr></table>

a Alinity i Toxo IgM reagent lot and Alinity i Toxo IgM calibrator lot are confounded, and the confounding effect is represented by between-lot. b Overall within-laboratory variability contains repeatability (within-run), between-run, between-day, and between-lot variance components. c Not applicable d In cases where $\mathbf { n } < 3 6 0$ , replicate(s) were excluded due to an instrument error and no results were reported.

Reproducibility Study (multi-site precision): A 5-day reproducibility study was conducted at 3 US sites, using the same samples panel used in the within-laboratory precision study, in addition to one positive and one negative controls. Four replicates per sample were evaluated in 2 runs per day over 5 days. The testing was performed using 3 lots of Alinity i Toxo IgM Reagents, 2 lots of Alinity i Toxo IgM Calibrators, and 1 lot of Alinity i Toxo IgM Controls at each of the 3 testing sites. The reproducibility data summary is shown in Table 3.

Table 3: Alinity i Toxo IgM Assay Reproducibility   

<table><tr><td rowspan=2 colspan=1>SampleID</td><td rowspan=2 colspan=1>n</td><td rowspan=2 colspan=1>MeanS/CO</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Site</td><td rowspan=1 colspan=2>Between-Lot a</td><td rowspan=1 colspan=2>Reproducibilityb</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>NegativeCControl</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.018</td><td rowspan=1 colspan=1>NAc</td></tr><tr><td rowspan=1 colspan=1>PositiveL Control</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>2.62</td><td rowspan=1 colspan=1>0.074</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.056</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.132</td><td rowspan=1 colspan=1>5.1</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.017</td><td rowspan=1 colspan=1>NAc</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>0.76</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>NAc</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>NAc</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.017</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.016</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.067</td><td rowspan=1 colspan=1>5.1</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>2.49</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.059</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.080</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.136</td><td rowspan=1 colspan=1>5.5</td></tr></table>

a Alinity i Toxo IgM reagent lot and Alinity i Toxo IgM calibrator lot are confounded, and the confounding effect is represented by between-lot. b Reproducibility contains repeatability, between-run, between-day, between-lot, betweensite, and site-lot interaction variance components. c Not applicable

2. Linearity:

Not applicable.

3. Analytical Specificity/Interference:

a. Potential Cross-Reactivity: Potential cross-reactivity for the Alinity i Toxo IgM assay was determined by testing a total of 177 serum samples from individuals with other medical conditions unrelated to Toxoplasmosis infection, in addition to samples from individuals with High titer Toxoplasma gondii IgG antibodies. Out of 10 Rheumatoid Factor specimens, one resulted in a false reactive result with the Alinity i Toxo IgM assay.

Table 4: Alinity i Toxo IgM Assay Cross-Reactivity study   

<table><tr><td rowspan=1 colspan=1>Potential Cross reactants</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Number ofAlinity i Toxo IgMFalse Reactive Results</td></tr><tr><td rowspan=1 colspan=1>Anti-dsDNA antibodies</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Anti-Nuclear Antibodies (ANA)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus (IgM)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Epstein-Barr virus (IgM)</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Herpes simplex virus types 1/2 (IgG/IgM)</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Human anti-mouse antibody (HAMA)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Hyper IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Hyper IgM</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Influenza vaccine recipients</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Measles (IgM)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Parvo-B19 virus (IgG)</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Parvo-B19 virus (IgM)</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor (RF)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1a</td></tr><tr><td rowspan=1 colspan=1>Rubella (IgM)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Samples from Immunocompromised patients</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Syphilis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Toxoplasmosis high Titer IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Varicella Zoster Virus</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>TOTAL</td><td rowspan=1 colspan=1>177</td><td rowspan=1 colspan=1>1</td></tr></table>

a One out of $1 0 \mathrm { R F }$ specimens was falsely reactive with the Alinity i Toxo IgM assay.

b. Potentially Interfering Endogenous Substances: The Alinity i Toxo IgM assay was evaluated for potential interference caused by endogenous substances. Each substance was evaluated using samples containing anti-Toxo $\mathrm { I g M }$ at the target ranges of 0.60 to $0 . 9 9 \mathrm { S } / \mathrm { C O }$ and 1.00 to 2.00 S/CO. No significant interference was observed at the following concentrations:

Table 5: Endogenous Interfering Substances Evaluated   

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Concentrations tested</td></tr><tr><td rowspan=1 colspan=1>Unconjugated bilirubin</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Conjugated bilirubin</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>3000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Total protein (high)</td><td rowspan=1 colspan=1>150 g/L</td></tr></table>

c. Potentially Interfering, Other Conditions: The Alinity i Toxo $\mathrm { I g M }$ assay was evaluated for potential interference caused by HAMA and RF using samples containing anti-Toxo $\mathrm { I g M }$ at the following target range: 1.00 to $1 . 4 0 \ : \mathrm { S / C O }$ . No significant interference was observed at the following concentrations:

Table 6: Potentially Interfering Other Conditions Evaluated   

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Concentrations tested</td></tr><tr><td rowspan=1 colspan=1>Human anti-mouse antibody (HAMA)</td><td rowspan=1 colspan=1>800 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor (RF)</td><td rowspan=1 colspan=1>200 IU/mL</td></tr></table>

d. Potentially Interfering Drugs and Other Substances: The Alinity i Toxo $\mathrm { I g M }$ assay was evaluated for potential interference caused by exogenous substances using samples containing anti-Toxo $\mathrm { I g M }$ at the target ranges of 0.60 to $0 . 9 9 \mathrm { S } / \mathrm { C O }$ and 1.00 to $2 . 0 0 \mathrm { S } / \mathrm { C O }$ . No significant interference was observed at the following concentrations:

Table 7: Exogenous Interfering Substances Evaluated   

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Concentrations tested</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>300 mg/L</td></tr><tr><td rowspan=1 colspan=1>Atovaquone</td><td rowspan=1 colspan=1>120 mg/L</td></tr><tr><td rowspan=1 colspan=1>Beta Carotene</td><td rowspan=1 colspan=1>6 mg/L</td></tr><tr><td rowspan=1 colspan=1>Biotin</td><td rowspan=1 colspan=1>4250 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Clindamycin</td><td rowspan=1 colspan=1>5.1 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Folic Acid</td><td rowspan=1 colspan=1>100 nmol/L</td></tr><tr><td rowspan=1 colspan=1>Pyrimethamine</td><td rowspan=1 colspan=1>15 mg/L</td></tr><tr><td rowspan=1 colspan=1>Spiramycine</td><td rowspan=1 colspan=1>4.2 mg/L</td></tr><tr><td rowspan=1 colspan=1>Sulfadiazine</td><td rowspan=1 colspan=1>25.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Sulfamethoxazole</td><td rowspan=1 colspan=1>210 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Trimethoprim</td><td rowspan=1 colspan=1>4.2 mg/dL</td></tr></table>

4. Assay Reportable Range: Not Applicable.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): Not Applicable.

6. Detection Limit: Not Applicable.

7. Assay Cut-Off:

The cut-off for the Alinity i Toxo IgM assay was established using samples characterized with a commercially available anti-Toxo IgM assay. A total of 1219 samples (1053 anti-Toxo IgM nonreactive samples, and 166 anti-Toxo IgM reactive samples) were included. A receiver-operating characteristic analysis supports a cut-off of 1.00 S/CO (with a grayzone from 0.83 to $1 . 0 0 \mathrm { S } / \mathrm { C O } )$ ).

# B Comparison Studies:

1. Method Comparison:

# Clinical Agreement:

A clinical study was conducted to evaluate the clinical performance of the Alinity i Toxo IgM assay. To evaluate the percent agreement between the Alinity i Toxo IgM assay and an FDA-cleared, commercially available anti-Toxo IgM assay with samples collected from two populations. Population 1 was comprised of 897 consecutively collected remnant specimens sent to a laboratory for anti-Toxo $\mathrm { I g M }$ testing including specimens collected in the US $\mathbf { \tilde { n } = }$ 169) and outside of the US $( { \bf n } = 7 1 0 )$ ), and Population 2 was comprised of 207 consecutively collected remnant specimens from pregnant women sent to a laboratory for anti-Toxo IgM testing in the US.

Demographic information for specimens collected in the US from Population 1 and 2 is shown in the Table 8 below $\scriptstyle ( \ n = 3 7 6 )$ .

Table 8: Subject Demographics (US specimens)   

<table><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Age</td><td rowspan=1 colspan=1>Female (n)</td><td rowspan=1 colspan=1>Male (n)</td><td rowspan=1 colspan=1>Unknown (n)</td><td rowspan=1 colspan=1>Total (n)</td></tr><tr><td rowspan=6 colspan=1>Population 1(n=169)</td><td rowspan=1 colspan=1>≤ 5 years</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>6 to 21 years</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>22 to 59 years</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>112</td></tr><tr><td rowspan=1 colspan=1>≥ 60 years</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>39</td></tr><tr><td rowspan=1 colspan=1>Unknown</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>169</td></tr><tr><td rowspan=6 colspan=1>Population 2(n=207)</td><td rowspan=1 colspan=1>≤ 5 years</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>6 to 21 years</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>22 to 59 years</td><td rowspan=1 colspan=1>196</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>196</td></tr><tr><td rowspan=1 colspan=1>≥ 60 years</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Unknown</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>207</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>207</td></tr><tr><td rowspan=6 colspan=1>Total</td><td rowspan=1 colspan=1>≤ 5 years</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>6 to 21 years</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>22 to 59 years</td><td rowspan=1 colspan=1>271</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>308</td></tr><tr><td rowspan=1 colspan=1>≥ 60 years</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>39</td></tr><tr><td rowspan=1 colspan=1>Unknown</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>309</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>376</td></tr></table>

Positive percent agreement (PPA) and negative percent agreement (NPA) between the Alinity I Toxo IgM assay and an FDA-cleared was calculated for each population separately and are shown in Tables 9 and 10 below.

Table 9: Alinity i Toxo IgM Clinical Performance - Population 1 $\mathrm { ( n = 8 9 7 ) }$ )   

<table><tr><td rowspan=2 colspan=1>Alinity i Toxo IgM</td><td rowspan=1 colspan=3>Comparator</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Reactive</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Grayzone/Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>Nonreactive</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>697</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>722</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>PPA</td><td rowspan=1 colspan=2>94.94% (150/158)</td><td rowspan=1 colspan=1>95%CI=90.33% to 97.41%</td></tr><tr><td rowspan=1 colspan=1>NPAa</td><td rowspan=1 colspan=2>94.44% (697/738)</td><td rowspan=1 colspan=1>95% CI=92.55% to 95.88%</td></tr></table>

a The $9 5 \%$ CI for PPA and NPA were estimated using the Wilson score method.

Table 10: Alinity i Toxo IgM Clinical Performance - Population $2 ^ { \mathrm { b } }$ $\scriptstyle ( \ n = 2 3 4 )$   

<table><tr><td rowspan=2 colspan=1>Alinity i Toxo IgM</td><td rowspan=1 colspan=3>Comparator</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Reactive</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Grayzone/Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Nonreactive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>215</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>215</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>PPA</td><td rowspan=1 colspan=2>94.74% (18/19)</td><td rowspan=1 colspan=1>95% CI=75.36% to 99.06%</td></tr><tr><td rowspan=1 colspan=1>NPAa</td><td rowspan=1 colspan=2>100.00% (215/215)</td><td rowspan=1 colspan=1>95% CI=98.24% to 100.00%</td></tr></table>

a The $9 5 \%$ CI for PPA and NPA were estimated using the Wilson score method. b Twenty seven specimens from Population 1 were from pregnant females and therefore, were also included in the Population 2.

# CDC Panel study:

The Centers for Disease Control and Prevention (CDC) Toxoplasma 1998 Human Serum Panel was tested using the Alinity i Toxo IgM assay. The Alinity i Toxo IgM assay results were submitted to the CDC for data analysis and for the result interpretation for each sample.

The panel consisted of 32 true positive Toxoplasma specimens and 65 true negative Toxoplasma specimens. The Alinity i Toxo IgM assay reported the 32 positive specimens as reactive and the 65 negative specimens, as nonreactive. The positive percent agreement

(PPA) was $100 \%$ with a $9 5 \%$ confidence interval (CI) of $8 9 . 2 8 \%$ to $1 0 0 . 0 0 \%$ . The negative percent agreement (NPA) was $100 \%$ with a $9 5 \%$ CI of $9 4 . 4 2 \%$ to $100 \%$ .

The results are presented as a means to convey further information on the performance of this assay with a masked, characterized serum panel. This does not imply endorsement of the assay by the CDC.

# 2. Matrix Equivalency:

A study was performed to evaluate whether specific blood collection tube types are suitable for use with the Alinity i Toxo IgM assay.

The matrix collection tube type equivalency study was conducted including 43 donors of reactive (20 donors) and nonreactive (23 donors) samples in 5 types of blood collection tubes; serum, serum separator, lithium heparin plasma, lithium heparin plasma (separator tube), and K3 EDTA plasma for use with the Alinity i Toxo IgM assay. Data was analyzed using regression comparing numerical S/CO value results of all matrices to serum. All of the blood collection tube types tested are acceptable for use with the Alinity i Toxo IgM assay.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable

2. Clinical Specificity: Not applicable

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable

D Clinical Cut-Off: Not applicable   
E Expected Values/Reference Range: Not applicable

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.